BRPI0919818A2 - inibidores de seprase seletivos - Google Patents
inibidores de seprase seletivosInfo
- Publication number
- BRPI0919818A2 BRPI0919818A2 BRPI0919818A BRPI0919818A BRPI0919818A2 BR PI0919818 A2 BRPI0919818 A2 BR PI0919818A2 BR PI0919818 A BRPI0919818 A BR PI0919818A BR PI0919818 A BRPI0919818 A BR PI0919818A BR PI0919818 A2 BRPI0919818 A2 BR PI0919818A2
- Authority
- BR
- Brazil
- Prior art keywords
- selective
- seprase
- inhibitors
- seprase inhibitors
- selective seprase
- Prior art date
Links
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 title 1
- 108010072257 fibroblast activation protein alpha Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic System
- C07F13/005—Compounds without a metal-carbon linkage
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10017808P | 2008-09-25 | 2008-09-25 | |
| PCT/US2009/058247 WO2010036814A1 (en) | 2008-09-25 | 2009-09-24 | Selective seprase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0919818A2 true BRPI0919818A2 (pt) | 2019-09-24 |
Family
ID=41305873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0919818A BRPI0919818A2 (pt) | 2008-09-25 | 2009-09-24 | inibidores de seprase seletivos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100098633A1 (pt) |
| EP (1) | EP2349995A1 (pt) |
| JP (1) | JP2012503670A (pt) |
| CN (1) | CN102203061A (pt) |
| AU (1) | AU2009296513A1 (pt) |
| BR (1) | BRPI0919818A2 (pt) |
| CA (1) | CA2737941A1 (pt) |
| RU (1) | RU2011116223A (pt) |
| TW (1) | TW201026335A (pt) |
| WO (1) | WO2010036814A1 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2823826A3 (en) | 2008-01-09 | 2015-03-25 | Molecular Insight Pharmaceuticals, Inc. | Inhibitors of carbonic anhydrase IX |
| CA2745955C (en) * | 2008-12-05 | 2017-05-23 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium- bis (heteroaryl) complexes and methods of use thereof for inhibiting psma |
| WO2010065899A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof |
| WO2010065906A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer |
| WO2010147965A2 (en) | 2009-06-15 | 2010-12-23 | Molecular Insight Pharmaceuticals, Inc. | Process for production of heterodimers of glutamic acid |
| WO2013103813A1 (en) | 2012-01-06 | 2013-07-11 | Molecular Insight Pharmaceuticals | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix |
| JP2015526402A (ja) * | 2012-06-29 | 2015-09-10 | ジーイー・ヘルスケア・リミテッド | 線維症のイメージング |
| ES2738474T3 (es) | 2013-01-14 | 2020-01-23 | Molecular Insight Pharm Inc | Radiofármacos a base de triazina y agentes radioimagenológicos |
| CN103992289B (zh) * | 2014-05-22 | 2016-04-06 | 河南全宇制药股份有限公司 | 取代噻唑烷氨荒酸铋配合物及其用途 |
| GB201613946D0 (en) * | 2016-08-15 | 2016-09-28 | Univ Oslo | Compounds |
| JP7162592B2 (ja) | 2016-12-14 | 2022-10-28 | パーデュー・リサーチ・ファウンデイション | 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療 |
| US11613785B2 (en) | 2017-01-09 | 2023-03-28 | Onkosxcel Therapeutics, Llc | Predictive and diagnostic methods for prostate cancer |
| US20200330624A1 (en) * | 2017-10-23 | 2020-10-22 | The Johns Hopkins University | Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (fap-alpha) |
| WO2019154859A1 (en) * | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
| CN114341158A (zh) | 2019-07-08 | 2022-04-12 | 3B制药有限公司 | 包含成纤维细胞活化蛋白配体的化合物及其用途 |
| EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| US20220273831A1 (en) | 2019-07-08 | 2022-09-01 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| KR20220158038A (ko) * | 2020-03-24 | 2022-11-29 | 트러스티즈 오브 터프츠 칼리지 | Fap-표적화된 방사성약제 및 영상화제 및 이와 관련된 용도 |
| CN112409414B (zh) * | 2020-12-01 | 2021-10-26 | 北京师范大学 | 锝-99m标记含异腈的FAPI衍生物及制备方法和应用 |
| CN116940585A (zh) | 2021-01-07 | 2023-10-24 | 3B制药有限公司 | 包含成纤维细胞活化蛋白配体的化合物及其用途 |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5601801A (en) * | 1994-08-02 | 1997-02-11 | Merck Frosst Canada, Inc. | Radiolabelled angiotensin converting enzyme inhibitors |
| US20060093552A1 (en) * | 2002-03-11 | 2006-05-04 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof |
| CA2555959A1 (en) * | 2004-02-12 | 2005-09-01 | Molecular Insight Pharmaceuticals | Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof |
| AU2006246719A1 (en) * | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| EP1760076A1 (en) * | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
| AU2007289168A1 (en) * | 2006-08-29 | 2008-03-06 | Molecular Insight Pharmaceuticals, Inc. | Radioimaging moieties coupled to peptidase-binding moieties for imaging tissues and organs that express peptidases |
-
2009
- 2009-09-24 RU RU2011116223/04A patent/RU2011116223A/ru unknown
- 2009-09-24 CA CA2737941A patent/CA2737941A1/en not_active Abandoned
- 2009-09-24 US US12/566,324 patent/US20100098633A1/en not_active Abandoned
- 2009-09-24 JP JP2011529228A patent/JP2012503670A/ja not_active Withdrawn
- 2009-09-24 CN CN2009801403238A patent/CN102203061A/zh active Pending
- 2009-09-24 AU AU2009296513A patent/AU2009296513A1/en not_active Abandoned
- 2009-09-24 WO PCT/US2009/058247 patent/WO2010036814A1/en active Application Filing
- 2009-09-24 EP EP09792960A patent/EP2349995A1/en not_active Withdrawn
- 2009-09-24 BR BRPI0919818A patent/BRPI0919818A2/pt not_active IP Right Cessation
- 2009-09-25 TW TW098132489A patent/TW201026335A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2737941A1 (en) | 2010-04-01 |
| EP2349995A1 (en) | 2011-08-03 |
| AU2009296513A1 (en) | 2010-04-01 |
| US20100098633A1 (en) | 2010-04-22 |
| TW201026335A (en) | 2010-07-16 |
| CN102203061A (zh) | 2011-09-28 |
| JP2012503670A (ja) | 2012-02-09 |
| RU2011116223A (ru) | 2012-10-27 |
| WO2010036814A1 (en) | 2010-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2020023I1 (el) | Αναστολεiς βητα-λακταμασων | |
| BRPI0919818A2 (pt) | inibidores de seprase seletivos | |
| CY2017016I2 (el) | Αναστολεις πρωτεασωματος | |
| BRPI0906764A2 (pt) | Processos | |
| BRPI0917808A2 (pt) | inibidores de cmet | |
| BRPI0919116A2 (pt) | método | |
| BRPI0907376A2 (pt) | Fotobiorretador | |
| DE602009000234D1 (de) | msignals | |
| BRPI0914649A2 (pt) | Piprazolo-quinazolinas | |
| DE602008003972D1 (de) | Sitzrücklehnungsmechanismus | |
| DE602008003521D1 (de) | Sitzrücklehnungsmechanismus | |
| BRPI0918564A2 (pt) | inibidores | |
| BRPI0814797A2 (pt) | Inibidores dna-pk | |
| DK2313489T3 (da) | Fremstillingsmetode | |
| DE602008003970D1 (de) | Strahlstromkalibriersystem | |
| BRPI0911625A2 (pt) | Métodos | |
| BRPI0907522A2 (pt) | biarlamidas | |
| DE112009001946A5 (de) | Mobelauszugsführung | |
| DE602009000488D1 (de) | Obstvereinzelvorrichtung | |
| DK2240506T3 (da) | IAP inhibitorer | |
| BRPI0907863A2 (pt) | pirrolopirimidinacarboxamidas | |
| BRPI0909634A2 (pt) | 2-aminoquinolinas | |
| DE112009000183A5 (de) | Sicherheitsvorreiber | |
| BRPI0916597A2 (pt) | Método | |
| BRPI0909637A2 (pt) | 2-aminoquinolinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |